Post by
alphaseeking001 on May 29, 2020 3:22pm
So... is this enough to move forward or not?
Any thoughts? 26% ORR in this population... good enough to move forward with a registration trial... or not? Honestly, it's hard for me to even put this in perspective at this point. I'm looking for Covid in the shorter term but does the ovarian data have legs... or not?
Comment by
Breakthorough1 on May 29, 2020 3:40pm
What F. Ors said in the CC in february was that the FED was going to say ok to anything with +20% ORR, good safety profile and +6months MDOR ("Median duration of response"). So Survivac is in the numbers. Does anyone know exactly hoy the 7.9 months of MDOR of PARP inhibitors were calculated? Did it included only the PRs or also the SD (so, the whole DCR)?
Comment by
pp19888 on May 29, 2020 7:48pm
Looks like only covid update could move this up. Next catalyst the mouse data and gov grants, phase 1 trial approval from HC. I'll ride it out the storm. Gl